15,601 Shares of Globus Medical, Inc. $GMED Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the 3rd quarter, Holdings Channel reports. The fund purchased 15,601 shares of the medical device company’s stock, valued at approximately $1,169,000.

A number of other large investors have also modified their holdings of the company. Elevation Wealth Partners LLC lifted its position in Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 305 shares during the last quarter. Continuum Advisory LLC bought a new position in Globus Medical in the 2nd quarter worth about $25,000. Root Financial Partners LLC bought a new position in Globus Medical in the 3rd quarter worth about $29,000. EverSource Wealth Advisors LLC grew its position in Globus Medical by 111.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,199 shares of the medical device company’s stock worth $103,000 after purchasing an additional 632 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Globus Medical by 63.3% in the first quarter. Parallel Advisors LLC now owns 1,778 shares of the medical device company’s stock valued at $153,000 after purchasing an additional 689 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Transactions at Globus Medical

In other news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ann Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the transaction, the director owned 35,384 shares in the company, valued at $3,007,640. This represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 60,000 shares of company stock valued at $4,838,400. Company insiders own 18.38% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on GMED. Canaccord Genuity Group cut their price target on Globus Medical from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday. Truist Financial reduced their price objective on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Royal Bank Of Canada decreased their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Wall Street Zen cut Globus Medical from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Needham & Company LLC cut their target price on Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.92.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Globus Medical Stock Down 0.5%

Shares of NYSE GMED opened at $70.67 on Monday. The stock has a market cap of $9.49 billion, a P/E ratio of 17.36, a P/E/G ratio of 1.14 and a beta of 0.98. The firm’s 50-day simple moving average is $77.20 and its 200 day simple moving average is $83.18. Globus Medical, Inc. has a fifty-two week low of $70.39 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The firm had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. Globus Medical’s revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts anticipate that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Globus Medical Company Profile